Biopharmaceutical company Arcus Biosciences has expanded its existing strategic relationship with Chinese company WuXi Biologics to discover anti-CD39 antibodies using the latter’s proprietary technology.

It is the fourth antibody development programme for which the two firms have collaborated.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the agreement, Arcus will gain exclusive worldwide rights to anti-CD39 antibodies discovered under the partnership and handle all their further development and commercialisation activities.

Preclinical experiments showed that the combination of CD39 inhibition with either CD73 or adenosine receptor inhibition gives a strong inhibition of ATP-adenosine axis and improved anti-tumour immunity, Arcus noted.

Arcus Biosciences research head and president Juan Jaen said: “Our relationship with WuXi Biologics started in 2017 with a clinic-ready anti-PD1 antibody, zimberelimab, which possesses molecular properties similar to those of marketed anti-PD1 therapies and has shown impressive clinical anti-tumour activity.

“Furthermore, WuXi Biologics has been an excellent manufacturing partner for our anti-TIGIT antibodies, domvanalimab (AB154) and AB308.”

Arcus currently has Etrumadenant (AB928), AB680, Domvanalimab (AB154) and Zimberelimab (AB122) molecules in the clinical development stage.

WuXi Biologics CEO Dr Chris Chen said: “We’re thrilled to expand our strategic partnership with Arcus Biosciences to further enable this innovative company to bring new biologics solutions using WuXi Biologics’ proprietary integrated platforms.

“We’re committed to offering global open-access technology platforms with premier quality standards to support our global partners as they build their innovative ideas into transformative new treatments for patients worldwide.”

The companies have not disclosed the financial terms of the deal.

In May, Arcus Biosciences has partnered with Gilead Sciences to jointly develop and commercialise current and future cancer therapeutic candidates in its pipeline.